Ultragenyx Pharmaceutical Inc. (RARE) · Aug 11, 2026 · Material agreement

DOJOLVI generic entry is deferred to 2033, but one patent fight ends

DOJOLVI generic entry is deferred to 2033, but one patent fight ends

The market already knew generic challengers were pursuing DOJOLVI. Ultragenyx had disclosed ANDA litigation involving Esjay and other filers, so the existence of a legal overhang was not new. Public filings identify DOJOLVI’s key patent protection as extending into 2034, while orphan-drug exclusivity runs only through June 30, 2027.

The settlement largely preserves near-term exclusivity, but gives up roughly a year versus the stated patent horizon. Esjay may launch its generic on January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted (Settlement terms). That is far later than the June 30, 2027 orphan-exclusivity date and removes the risk of an immediate adverse court ruling against this specific challenger, but it is earlier than the 2034 patent expiration referenced in the company’s filings. The agreement is also royalty-free, so the filing discloses no offsetting settlement revenue (Settlement terms).

The net read is mixed rather than clearly positive. There is no reliable published consensus for the outcome of this patent case. Relative to a favorable litigation outcome, a 2033 launch is a modest concession; relative to the risk that Esjay could win earlier, it is protective. Because other DOJOLVI ANDA lawsuits remain pending, this resolves only one challenger and does not eliminate the broader generic-entry uncertainty (Other Events). DOJOLVI generated $96 million in 2025 and Ultragenyx guided to $100 million-$110 million for 2026, making the asset meaningful but not the company’s largest revenue driver.

Original filing on SEC EDGAR

More Ultragenyx Pharmaceutical Inc. news

DOJOLVI generic entry is deferred to 2033, but one patent fight ends | RARE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.